Scancell Holdings Plc · LSE:SCLP
Scancell — Society for Immunotherapy of Cancer (SITC) 40th Anniversary Annual Meeting 2025
16 slides from Scancell's conference presentation, November 2025
Slide 1: SITC 40th Anniversary Annual Meeting, National Harbor, MD
4 TH 4 a Society for Immunotherapy of Cancer ANNIVERSARY Nov. 5-9 | National Harbor, MD
Slide 2: SCOPE, a phase 2 trial with DNA plasmid immunotherapy in advanced melanoma combined with check point blockade
SCOPE, a phase 2 trial with DNA plasmid immunotherapy in advanced melanoma combined with check point blockade An interim read-out of SCOPE, an open label parallel multi cohort translational study evaluating an off-the-shelf DNA plasmid vaccine in first line advanced melanoma combined with check poin
Slide 3: Disclosures
Disclosures • Serve as full time Chief Medical Officer at Scancell Ltd, UK – study sponsor
Slide 4: SCIB1 & iSCIB1+ are off-the-shelf DNA plasmid vaccines with CD8 & CD4 epitopes from TRP-2 and gp100
SCIB1 & iSCIB1+ are off-the-shelf DNA plasmid vaccines with CD8 & CD4 epitopes from TRP-2 and gp100. • SCIB1 and iSCIB1 + incorporate CD8 and CD4 epitopes from TRP-2 and gp100 into an antibody framework to allow direct and Fc targeting of activated dendritic cells • TRP-2 and gp 100 epitopes that ha
Slide 5: Dual mode of action to maximise anti-tumour immune response following needle free injection
Dual mode of action to maximise anti-tumour immune response following needle free injection • By Direct Presentation ImmunoBody targets antigen presenting cells (APCs) via CD64 causing expression of engineered antibodies • By Cross Presentation secretion of the engineered antibody targeted to CD64 F
Slide 6: SCOPE Program - advanced melanoma with checkpoint inhibitors
SCOPE Program - advanced melanoma with checkpoint inhibitors Phase 2 open label multi cohort translational study enrolling over 140 patients with start in 2022. Objective: select product, target population, dosing schedule and endpoints for follow-on phase 3 trial STUDY POPULATION Cohort 1 (n=43) Se
Slide 7: SCOPE: Study Partners and Schema
SCOPE: Study Partners and Schema Conducted at 16 UK Clinical Trial Sites Study Schema & Dosing Schedule
Slide 8: Across cohorts in HLA matched patients there were strong T cell responses correlated with clinical response
Across cohorts in HLA matched patients there were strong T cell responses correlated with clinical response. Best T cell response Cohort 3 1400 T-cell Responses - ELISpot Assays (n=33) 1300 <0.0001 Nomalised spot count per million cultured PBMCs POSITIVE 1200 CLINICAL NUMBER OF T CELL % POSITIVE 110
Slide 9: Cells with iSCIB1+ reactive TCRs show strong cytotoxic signature
Cells with iSCIB1+ reactive TCRs show strong cytotoxic signature 888 IFNγ+ CD8 T cells from 5 patients Functionality Killing Proliferation One dot per cell Grey = no expression Strong expression of granzyme B, perforin confirms CD8 activation.
Slide 10: Clinical Response with SCIB1 in cohort 1: Interim Read-Out
Clinical Response with SCIB1 in cohort 1: Interim Read-Out Progression Free Survival (n=41) RECIST 1.1 Best Overall Response: Waterfall Plot PD SD PR CR RESPONSES Average Change (%) PFS at 23 months = 55.6% ORR: 63.4% (26/41) 7 8 18 8 DCR: 82.9% (34/41) Median PFS for checkmate 067 = 11.5 mths, not
Slide 11: Clinical Response with iSCIB1+ in cohort 3: Interim Read-Out
Clinical Response with iSCIB1+ in cohort 3: Interim Read-Out Progression Free Survival (n=42) vs Checkmate - 067 RECIST 1.1 Best Overall Response: Waterfall Plot PD SD PR CR RESPONSES ORR: 64.5% (20/31) PFS at 11 months = 77.8% 6 5 16 4 DCR: 80.6% (25/31) 27% ∆ PFS at 11 months = 50% PD – new lesion
Slide 12: Durable Response with SCIB & iSCIB1+ amongst matched HLA patients in Cohorts 1&3
Durable Response with SCIB & iSCIB1+ amongst matched HLA patients in Cohorts 1&3. Durable Response on Spider Plot: Cohort 1 (n=41) Durable Response on Spider Plot: Cohort 3 (n=31) Study Week Study Week 49 12
Slide 13: Clinical Response in HLA matched patients with SCIB1 / iSCIB1+ in cohorts 1 & 3
Clinical Response in HLA matched patients with SCIB1 / iSCIB1+ in cohorts 1 & 3: Interim Read-Out RECIST 1.1 Best Overall Response: Waterfall Plot Progression Free Survival (n=72) vs Checkmate – 067 >20 % ∆ Median PFS for checkmate 067 = 11.5 mths Median PFS for SCOPE not yet reached Interim Data Re
Slide 14: Interim Safety Summary – SCIB1 and iSCIB1+ (n = 133)
Interim Safety Summary – SCIB1 and iSCIB1+ (n = 133) The safety profile of SCIB1 / iSCIB1+ is benign with no potentiation of the toxicities of the checkpoint inhibitors. Related to SCIB1 or iSCIB1+ Related to checkpoint inhibitors TEAE 292 in 75 (56%) patients 867 in 116 (87%) patients Majority comp
Slide 15: Conclusions and Next Steps
Conclusions and Next Steps Efficacy benefit, Durability & Tolerability of iSCIB1+ confirmed with Progression Free Survival improvement set to be a critical end point HLA matched population with either MHC – class 1 A2, A3, A31, Bw4, B44, B35 comprising 80% of the patient population identified Stable
Slide 16: Acknowledgements and Appreciation
Acknowledgements and Appreciation Investigators and Clinical Trial Sites Scancell Team Georgia Goodhew Heather Shaw - University College London Hospital Joe Thornton Pippa Corrie - Addenbrooke's Hospital, Cambridge Robert Miller Sarah Danson - Weston Park Cancer Centre, Sheffield Teaching Hospital N